Northside Hospital Chooses MRIdian System to Expand Advanced Radiation Therapy Treatment Services

MRIdian A3i includes a suite of new features to streamline on-table adaptive workflow and provide the potential to reduce treatment times, along with a new brain treatment package expanding clinical utility into cranial stereotactic radiosurgery (SRS) and stereo (NASDAQ: VRAY) today announced that the company received FDA 510(k) clearance for its next generation of MRI-guided radiation therapy features, focused on enhancing on-table adaptive workflow and expanding clinical utility. ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features (NASDAQ: VRAY) today announced its participation in the 40th Annual J.P.

ViewRay to Participate in the 40th Annual J.P. Over the past 66 months, VRAY's EV/EBIT ratio has gone down 4.1.Д«elow are key valuation metrics over time for VRAY.Д«elow are the latest news stories about ViewRay Inc that investors may wish to consider to help them evaluate VRAY as an investment opportunity.Over the past 66 months, VRAY's price/sales ratio has gone up 1.VRAY's price/sales ratio is 16.8 this is 48.02% higher than that of the median Healthcare stock.To visit the company's web site, go to VRAY Valuation Summary Visit VRAY's SEC page to see the company's official filings.If you're looking for stocks that are quantitatively similar to ViewRay Inc, a group of peers worth examining would be FROG, VUZI, LNSR, VRCA, and ZUO.VRAY's price/sales ratio is 13.14 that's higher than the P/S ratio of 86.73% of US stocks.VRAY's went public 5.75 years ago, making it older than just 20.97% of listed US stocks we're tracking.VRAY's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 139.22 - higher than 82.21% of US-listed equities with positive expected earnings growth.VRAY's current lowest rank is in the Quality metric (where it is better than 6.13% of US stocks).The strongest trend for VRAY is in Stability, which has been heading down over the past 139 days.

Growth is the dimension where VRAY ranks best there it ranks ahead of 77.78% of US stocks.

Vray price